Top

Open Access 29-08-2024 | Systemic Sclerosis | REVIEW ARTICLE

Biomarkers reflecting the pathogenesis, clinical manifestations, and guide therapeutic approach in systemic sclerosis: a narrative review

Authors: Anna Bazsó, Péter Szodoray Med Dsci, Yehuda Shoenfeld, Emese Kiss Med Dsci

Abstract

Systemic sclerosis (SSc) is a progressive autoimmune disorder that mainly affects the skin. There are other clinical manifestations as renal, pulmonary, cardiovascular, and gastrointestinal tract involvements. Based on the skin involvement there are two subtypes of SSc, as limited cutaneous SSc (lSSc) which involves the acral part of the body and diffuse cutaneous SSc (dSSc) resulting in significant skin thickening of the body. Despite of the extensive research the pathomechanism is not fully clarified, how Ssc develops, moreover identifying biomarkers to predict the clinical outcome and prognosis still remains challenging. Circulating biomarkers can be crucial to define the diagnosis, to predict the prognosis and monitor the clinical course. However, only some patients are responsive to the therapy in SSc, and there is a need to reach the ideal therapy for any individual to prevent or slow down the progression in early stages of the disease. In this narrative review, our purpose was to summarize the potential biomarkers in Ssc, describe their role in the diagnosis, pathomechanism, clinical course, organ manifestations, as well as the response to the therapy. Biomarkers assessment aids in the evaluation of disease progression, and disease outcome.

Rosendahl A, Schönborn K, Krieg T (2022) Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci 38:187–195. https://doi.org/10.1002/kjm2.12505CrossRefPubMed

Keret S, Rimar D, Lansiaux P et al (2023) Differentially expressed genes in systemic sclerosis: towards predictive medicine with new molecular tools for clinicians. Autoimmun Rev 22:103314. https://doi.org/10.1016/j.autrev.2023.213324CrossRefPubMed

Gourh P, Safran SA, Alexander T et al (2020) HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. Proc Natl Acad Sci 117:552–562. https://doi.org/10.1073/pnas.1906593116CrossRefPubMed

Abignano G, Hermes H, Piera-Velazquez S et al (2021) Global gene expression analysis of systemic sclerosis myofibroblasts demonstrates a marked increase in the expression of multiple NBPF genes. Sci Rep 11:20435. https://doi.org/10.1038/s41598-021-99292-yCrossRefPubMedPubMedCentral

Stern EP, Denton CP (2015) The pathogenesis of systemic sclerosis. Rheum Dis Clin North Am 41:367–382. https://doi.org/10.1016/j.rdc.2015.04.002CrossRefPubMed

Kerick M, González-Serna D, Carnero-Montoro E et al (2021) Expression quantitative trait locus analysis in systemic sclerosis identifies new candidate genes associated with multiple aspects of disease pathology. Arthritis Rheumatol 73:1288–1300. https://doi.org/10.1002/art.41657CrossRefPubMed

Zhou X, Tan FK, Wang N et al (2003) Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 48:2585–2592. https://doi.org/10.1002/art.11220CrossRefPubMed

Wasson CW, Abignano G, Hermes H et al (2020) Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH. Ann Rheum Dis 79:507–517. https://doi.org/10.1136/annrheumdis-2019-216542CrossRefPubMed

Fearon AE, Slabber CF, Kuklin A et al (2021) Fibroblast growth factor receptor 3 in hepatocytes protects from toxin-induced liver injury and fibrosis. iScience 24:103143. https://doi.org/10.1016/j.isci.2021.103143CrossRefPubMedPubMedCentral

10.

Cutulo M, Soldano S, Smith S (2019) Pathophysiology of systemic sclerosis: current understanding and newinsight. Expert Rev Clin Immunol 15:753–764. https://doi.org/10.1080/1744666X.2019.1614915CrossRef

11.

Chizzolini C, Boin F (2015) The role of the acquired immune response in systemic sclerosis. Semin Immunopathol 37:519–528. https://doi.org/10.1007/s00281-015-0509-1CrossRefPubMed

12.

Asano Y (2020) The pathogenesis of systemic sclerosis: an understanding based on common pathologic cascade across multiple organs and additional organ-specific pathologies. J Clin Med 9:2687. https://doi.org/10.3390/jcm9092687CrossRefPubMedPubMedCentral

13.

Bellando-Randone S, Matucci-Cerinic M (2019) Very early systemic sclerosis. Best Pract Res Clin Rheumatol 33:101428. https://doi.org/10.1016/j.berh.2019.101428CrossRefPubMed

14.

Frantz C, Auffray C, Avouac J (2018) Regulatory T cells in systemic sclerosis. Font Immunol 15(9):2356. https://doi.org/10.3389/fimmu.2018.02356CrossRef

15.

Sakkas LI, Katsiari CG, Daoussis D, Bogdanos DP (2023) The role of B cells in the pathogenesis of systemic sclerosis: an update. Rheumatology 62:1780–1786. https://doi.org/10.1093/rheumatology/keac578CrossRefPubMed

16.

Negrini S, Fenoglio D, Parodi A et al (2017) Phenotypic alterations involved in CD8+ treg impairment in systemic sclerosis. Front Immunol 8:18. https://doi.org/10.3389/fimmu.2017.00018CrossRefPubMedPubMedCentral

17.

Ah Kioon MD, Tripodo C, Fernandez D et al (2018) Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Sci Transl Med 10:eaam845. https://doi.org/10.1126/scitranslmed.aam8458CrossRef

18.

Khalil N, Bereznay O, Sporn M, Greenberg AH (1989) Macrophage production of transforming growth factor β and fibroblast collagen synthesis in chronic pulmonary inflammation. J Exp Med 170:737–737. https://doi.org/10.1084/jem.170.3.727CrossRef

19.

Trombetta AC, Soldano S, Contini P et al (2018) A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement. Respir Res 19:186. https://doi.org/10.1186/s12931-018-0891-zCrossRefPubMedPubMedCentral

20.

Rech TF, Moraes SBC, Bredemeier M, et al (2016) Matrix metalloproteinase gene polymorphisms and susceptibility to systemic sclerosis. Genet Mol Res 15. https://doi.org/10.4238/gmr15049077.

21.

Asano Y, Sato S (2015) Vasculopathy in scleroderma. Semin Immunopathol 37:489–500. https://doi.org/10.1007/s00281-015-0505-5CrossRefPubMed

22.

Hinz B, Phan SH, Thannickal VJ et al (2007) The myofibroblast: one function, multiple origins. Am J Pathol 170:1807–1816. https://doi.org/10.2353/ajpath.2007.070112CrossRefPubMedPubMedCentral

23.

Khanna D, Furst DE, Clements PJ et al (2017) Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord 2:11–18. https://doi.org/10.5301/jsrd.5000231CrossRefPubMed

24.

Jerjen R, Nikpour M, Krieg T et al (2022) Systemic sclerosis in adults. Part I: Clinical features and pathogenesis. J Am Acad Dermatol 87:937–954. https://doi.org/10.1016/j.jaad.2021.10.065CrossRefPubMed

25.

Riccardi A, Martinroche G, Contin-Bordes C et al (2022) Erosive arthritis autoantibodies in systemic sclerosis. Semin Arthritis Rheum 52:151947. https://doi.org/10.1016/j.semarthrit.2021.11.013CrossRefPubMed

26.

Sakchaikul A, Chowchuen P, Foocharoen C, Thammaroj P (2021) Prevalence and clinical association with acro-osteolysis in early systemic sclerosis. Clin Exp Rheumatol 39:1093–1098. https://doi.org/10.55563/clinexprheumatol/vggbdqCrossRefPubMed

27.

Ostojic P, Knezevic-Apostolski S, Djurovic N et al (2021) Neurological and electroneurography findings in patients with systemic sclerosis and symptoms of neuropathic pain in extremities. Acta Neurol Belg 121:205–209. https://doi.org/10.1007/s13760-018-1048-zCrossRefPubMed

28.

Smith V, Ickinger C, Hysa E et al (2023) Naifold capillaroscopy. Best Pact Res Clin Rheumatol 37:101849. https://doi.org/10.1016/j.berth.2023.101849CrossRef

29.

Muktabhant C, Thammaroj P, Chowchuen P, Foocharoen C (2021) Prevalence and clinical association with calcinosis cutis in early systemic sclerosis. Mod Rheumatol 31:1113–1119. https://doi.org/10.1080/14397595.2021.1886654CrossRefPubMed

30.

Chatterjee S, Prayson RA (2020) Concurrent anti-PM-Scl antibody-associated systemic sclerosis and inclusion body myositis—report of two cases and review of the literature. Semin Arthritis Rheum 50:498–502. https://doi.org/10.1016/j.semarthrit.2019.11.008CrossRefPubMed

31.

Muangchan C, Harding S, Khimdas S et al (2012) Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res 64:1405–1414. https://doi.org/10.1002/acr.21716CrossRef

32.

Young A, Moles VM, Jaafar S et al (2021) Performance of the DETECT algorithm for pulmonary hypertension screening in a systemic sclerosis cohort. Arthritis Rheumatol 73:1731–1737. https://doi.org/10.1002/art.41732CrossRefPubMedPubMedCentral

33.

Meyer KC, Raghu G, Baughman RP et al (2012) An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 185:1004–1014. https://doi.org/10.1164/rccm.201202-0320STCrossRefPubMed

34.

Ma L, Zhu Q, Zhang Y et al (2021) Esophagus involvement in systemic sclerosis: ultrasound parameters and association with clinical manifestations. Arthritis Res Ther 23:122. https://doi.org/10.1186/s13075-021-02505-yCrossRefPubMedPubMedCentral

35.

Shan Y, Lee M, Chang EB (2022) The gut microbiome and inflammatory bowel diseases. Annu Rev Med 73:455–468. https://doi.org/10.1146/annurev-med-042320-021020CrossRefPubMed

36.

Stec A, Maciejewska M, Zaremba M et al (2023) The clinical significance of serum biomarkers of the intestinal barrier in systemic sclerosis: a cross-sectional study. J Pers Med 13:678. https://doi.org/10.3390/jpm13040678CrossRefPubMedPubMedCentral

37.

Kawagachi Y, Kuwana M (2023) Is there a role for the microbiome in systemic sclerosis? Expert Rev Clin Immunol 19:237–240. https://doi.org/10.1080/1744666X.2023.2161512CrossRef

38.

Bramer WM (2018) A systemic approach to searching: an efficient and complete method to develop literature searches. J Med Libr Assoc 106(4):531–541. https://doi.org/10.5195/jmla.2018.283CrossRefPubMedPubMedCentral

39.

Horvath AR, Lord SJ, StJohn A et al (2014) From biomarkers to medical tests: the changing landscape of test evaluation. Clin Chim Acta 427:49–57. https://doi.org/10.1016/j.cca.2013.09.018CrossRefPubMed

40.

Stochmal A, Czuwara J, Trojanowska M, Rudnicka L (2020) Antinuclear antibodies in systemic sclerosis: an update. Clin Rev Allergy Immunol 58:40–51. https://doi.org/10.1007/s12016-018-8718-8CrossRefPubMed

41.

Papaioannou AI, Zakynthinos E, Kostikas K et al (2009) Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis. BMC Pulm Med 9:18. https://doi.org/10.1186/1471-2466-9-18CrossRefPubMedPubMedCentral

42.

Rokni M, Sadeghi Shaker M, Kavosi H et al (2022) The role of endothelin and RAS/ERK signaling in immunopathogenesis-related fibrosis in patients with systemic sclerosis: an updated review with therapeutic implications. Arthritis Res Ther 24:108. https://doi.org/10.1186/s13075-022-02787-wCrossRefPubMedPubMedCentral

43.

Bellando-Randone S, Matucci-Cerinic M (2014) From Raynaud’s phenomenon to very early diagnosis of systemic sclerosis—the VEDOSS approach. Curr Rheumatol Rev 9:245–248. https://doi.org/10.2174/157339710904140417124819CrossRef

44.

Patnaik E, Lyons M, Tran K, Pattanaik D (2023) Endotheial dysfunction in systemic sclerosis. Int J Mol Sci 24:14385. https://doi.org/10.3391/ijms241814385CrossRefPubMedPubMedCentral

45.

Ho KT, Reveille JD (2003) The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 5:80–93. https://doi.org/10.1186/ar628CrossRefPubMedPubMedCentral

46.

Volpe A, Ruzzenente O, Caramaschi P et al (2009) Clinical associations of anti-CENP-B and anti-Scl70 antibody levels measured by multiplexed fluorescent microsphere immunoassay in systemic sclerosis. Rheumatol Int 29:1073–1079. https://doi.org/10.1007/s00296-009-0868-9CrossRefPubMed

47.

Okano Y, Steen VD, Medsger TA (1993) Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119:1005–1013. https://doi.org/10.7326/0003-4819-119-10-199311150-00007CrossRefPubMed

48.

Mahler M, Meroni P-L, Bossuyt X, Fritzler MJ (2014) Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res 2014:1–18. https://doi.org/10.1155/2014/315179CrossRef

49.

Betteridge ZE, Woodhead F, Lu H et al (2016) Brief report: anti–eukaryotic initiation factor 2B autoantibodies are associated with interstitial lung disease in patients With systemic sclerosis. Arthritis Rheumatol 68:2778–2783. https://doi.org/10.1002/art.39755CrossRefPubMed

50.

Pauling JD, Salazar G, Lu H et al (2018) Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. Rheumatol (United Kingdom) 57:712–717. https://doi.org/10.1093/rheumatology/kex458CrossRef

51.

Fertig N, Domsic RT, Rodriguez-Reyna T et al (2009) Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Care Res 61:958–965. https://doi.org/10.1002/art.24586CrossRef

52.

Wirtz D, Schulte-Pelkum J, Budde P, et al (2015) Development of a qualitative ELISA for the detection of anti-BICD2 autoantibodies in systemic sclerosis. In: 12th Dresden Symposium on Autoantibodies, P53. Dresden

53.

Chan EKL (2022) Anti-Ro52 autoantibody is common in systemic autoimmune rheumatic diseases and correlating with worse outcome when associated with interstitial lung disease in systemic sclerosis and autoimmune myositis. Clin Rev Allergy Immunol 63:178–193. https://doi.org/10.1007/s12016-021-08911-zCrossRefPubMed

54.

Mahler M, Swart A, Wu J et al (2016) Clinical and serological associations of autoantibodies to the Ku70/Ku80 heterodimer determined by a novel chemiluminescent immunoassay. Lupus 25:889–896. https://doi.org/10.1177/0961203316640918CrossRefPubMed

55.

Mahler M, Fritzler MJ (2009) The changing landscape of the clinical value of the PM/Scl autoantibody system. Arthritis Res Ther 11:106. https://doi.org/10.1186/ar2646CrossRefPubMedPubMedCentral

56.

Airo’CeribelliCavazzana PAI et al (2011) Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 38:1329–1334. https://doi.org/10.3899/jrheum.101144CrossRef

57.

Moinzadeh P, Fonseca C, Hellmich M et al (2014) Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 16:R53. https://doi.org/10.1186/ar4486CrossRefPubMedPubMedCentral

58.

Xu GJ, Shah AA, Li MZ et al (2016) Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Proc Natl Acad Sci U S A 113:E7526–E7534. https://doi.org/10.1073/pnas.1615990113CrossRefPubMedPubMedCentral

59.

Nakamura K, Asano Y, Taniguchi T et al (2016) Serum levels of interleukin-18-binding protein isoform a: clinical association with inflammation and pulmonary hypertension in systemic sclerosis. J Dermatol 43:912–918. https://doi.org/10.1111/1346-8138.13252CrossRefPubMed

60.

Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24:328–332PubMed

61.

Bălănescu P, Lădaru A, Bălănescu E et al (2015) IL-17, IL-6 and IFN-γ in systemic sclerosis patients. Rom J Intern Med 53:44–49. https://doi.org/10.1515/rjim-2015-0006CrossRefPubMed

62.

Robak E, Kulczycka-Siennicka L, Gerlicz Z et al (2013) Correlations between concentrations of interleukin (IL)-17A, IL-17B and IL-17F, and endothelial cells and proangiogenic cytokines in systemic lupus erythematosus patients. Eur Cytokine Netw 24:60–68. https://doi.org/10.1684/ecn.2013.0330CrossRefPubMed

63.

Xu B, Xu G, Yu Y, Lin J (2021) The role of TGF-β or BMPR2 signaling pathway-related miRNA in pulmonary arterial hypertension and systemic sclerosis. Arthritis Res Ther 23:288. https://doi.org/10.1186/s13075-021-02678-6CrossRefPubMedPubMedCentral

64.

Bukiri H, Volkmann ER (2022) Current advances in the treatment of systemic sclerosis. Curr Opin Pharmacol 64:102211. https://doi.org/10.1016/j.coph.2022.102211CrossRefPubMedPubMedCentral

65.

Khanna D, Lin CJF, Furst DE et al (2022) Long-term safety and efficacy of tocilizumab in early systemic sclerosis–interstitial lung disease: open-label extension of a phase 3 randomized controlled trial. Am J Respir Crit Care Med 205:674–684. https://doi.org/10.1164/rccm.202103-0714OCCrossRefPubMed

66.

O’Reilly S, Cant R, Ciechkomaka M, van Laar JM (2013) Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunol 2. https://doi.org/10.1038/cti.2013.2

67.

Jalce G, Guignabert C (2020) Multiple roles of macrophage migration inhibitory factor in pulmonary hypertension. Am J Physiol Cell Mol Physiol 318:L1–L9. https://doi.org/10.1152/ajplung.00234.2019CrossRef

68.

Frantz C, Cauvet A, Durand A et al (2022) Driving role of interleukin-2–related regulatory CD4+ T cell deficiency in the development of lung fibrosis and vascular remodeling in a mouse model of systemic sclerosis. Arthritis Rheumatol 74:1387–1398. https://doi.org/10.1002/art.42111CrossRefPubMed

69.

Kosałka-Węgiel J, Lichołai S, Dziedzina S et al (2022) Genetic association between TNFA polymorphisms (rs1799964 and rs361525) and susceptibility to cancer in systemic sclerosis. Life 12:698. https://doi.org/10.3390/life12050698CrossRefPubMedPubMedCentral

70.

Lykhopiy V, Malviya V, Humblet-Baron S, Schlenner SM (2023) IL-immunotherapy for targeting regulatory T cells in autoimmunity. Genes Immun 24:248–262. https://doi.org/10.1038/s41435-023-00221-yCrossRefPubMedPubMedCentral

71.

King J, Abraham D, Stratton R (2018) Chemokines in systemic sclerosis. Immunol Lett 195:68–75. https://doi.org/10.1016/j.imlet.2017.12.001CrossRefPubMed

72.

Khanna D, Tashkin DP, Denton CP et al (2020) Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med 201:650–660. https://doi.org/10.1164/rccm.201903-0563CICrossRefPubMedPubMedCentral

73.

Furukawa T, Matsui K, Kitano M et al (2019) Relationship between YKL-40 and pulmonary arterial hypertension in systemic sclerosis. Mod Rheumatol 29:476–483. https://doi.org/10.1080/14397595.2018.1480256CrossRefPubMed

74.

Machahua C, Guler SA, Horn MP et al (2021) Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts. BMJ Open Respir Res 8:e000827. https://doi.org/10.1136/bmjresp-2020-000827CrossRefPubMedPubMedCentral

75.

Boleto G, Allanore Y, Avouac J (2018) Targeting costimulatory pathways in systemic sclerosis. Front Immunol 9:2998. https://doi.org/10.3389/fimmu.2018.02998CrossRefPubMedPubMedCentral

76.

Romano E, Rosa I, Fioretto BS et al (2019) A new avenue in the pathogenesis of systemic sclerosis: the molecular interface between the endothelial and the nervous systems. Clin Exp Rheumatol 37(Suppl 1):133–140PubMed

77.

Romano E, Rosa I, Fioretto BS et al (2022) Circulating neurovascular guidance molecules and their relationship with peripheral microvascular impairment in systemic sclerosis. Life 12:1056. https://doi.org/10.3390/life12071056CrossRefPubMedPubMedCentral

78.

Mazzotta C, Romano E, Bruni C et al (2015) Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis. Arthritis Res Ther 17:221. https://doi.org/10.1186/s13075-015-0749-4CrossRefPubMedPubMedCentral

79.

Michalska-Jakubus M, Potembska E, Kowal M et al (2019) Clinical associations of serum leptin and leptin/adiponectin ratio in systemic sclerosis. Postep Dermatologii Alergol 36:325–338. https://doi.org/10.5114/ada.2018.75809CrossRef

80.

Pehlivan Y, Onat AM, Ceylan N et al (2012) Serum leptin, resistin and TNF-α levels in patients with systemic sclerosis: the role of adipokines in scleroderma. Int J Rheum Dis 15:374–379. https://doi.org/10.1111/j.1756-185X.2012.01755.xCrossRefPubMed

81.

Sundblad V, Gomez RA, Stupirski JC et al (2021) Circulating galectin-1 and galectin-3 in sera from patients with systemic sclerosis: associations with clinical features and treatment. Front Pharmacol 12:650605. https://doi.org/10.3389/fphar.2021.650605CrossRefPubMedPubMedCentral

82.

Miura S, Asano Y, Saigusa R et al (2015) Serum vaspin levels: a possible correlation with digital ulcers in patients with systemic sclerosis. J Dermatol 42:528–531. https://doi.org/10.1111/1346-8138.12810CrossRefPubMed

83.

Sawicka K, Michalska-Jakubus M, Potembska E et al (2019) Visfatin and chemerin levels correspond with inflammation and might reflect the bridge between metabolism, inflammation and fibrosis in patients with systemic sclerosis. Postep Dermatologii i Alergol 36:551–565. https://doi.org/10.5114/ada.2018.79104CrossRef

84.

Sanges S, Rice L, Tu L et al (2023) Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis. Ann Rheum Dis 82:365–373. https://doi.org/10.1136/ard-2022-223237CrossRefPubMed

85.

Hasegawa M, Asano Y, Endo H et al (2014) Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study. PLoS One 6(9):e88150. https://doi.org/10.1371/journal.pone.0088150. (eCollection 2014)CrossRef

86.

Kuszmiersz P, Pacholczak-Madej R, Siwiec A et al (2021) Thrombin generation potential is enhanced in systemic sclerosis: impact of selected endothelial biomarkers. Clin Exp Rheumatol 131:13–19. https://doi.org/10.55563/clinexprheumatol/d03dncCrossRef

87.

Ren H, Liu L, Xiao Y et al (2023) Further insight into systemic sclerosis from the vasculopathy perspective. Biomed Pharmacother. https://doi.org/10.1016/j.biopha.2023.115282CrossRefPubMed

88.

Gigante A, NavariniMargiotta LD et al (2017) Angiogenic and angiostatic factors in renal scleroderma-associated vasculopathy. Microvasc Res 114:41–45. https://doi.org/10.1016/j.mvr.2017.06.003CrossRefPubMed

89.

Luo JY, Liu X, Jiang M et al (2017) Oxidative stress markers in blood in systemic sclerosis: a meta-analysis. Mod Rheumatol 27:306–314. https://doi.org/10.1080/14397595.2016.1206510CrossRefPubMed

90.

Doridot L, Jeljeli M, Chệne C, Batteux F (2019) Implication of oxidative stress in the pathogenesis of systemic sclerosis via inflammation, autoimmunity and fibrosis. Redox Biol 25:101122. https://doi.org/10.1016/j.redox.2019.101122CrossRefPubMedPubMedCentral

91.

Cumpstey A, Feelisch M (2017) Free radicals in inflammation. Inflammation—from molecular and cellular mechanisms to the clinic. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, pp 695–726CrossRef

92.

Chettimada S, Ata H, Rawat DK et al (2014) Contractile protein expression is upregulated by reactive oxygen species in aorta of Goto-Kakizaki rat. Am J Physiol Circ Physiol 306:H214–H224. https://doi.org/10.1152/ajpheart.00310.2013CrossRef

93.

Dimmeler S, Zeiher AM (2000) Reactive oxygen species and vascular cell apoptosis in response to angiotensin II and pro-atherosclerotic factors. Regul Pept 90:19–25. https://doi.org/10.1016/S0167-0115(00)00105-1CrossRefPubMed

94.

Cortese-Krott MM, Koning A, Kuhnle GGC et al (2017) The reactive species interactome: evolutionary emergence, biological significance, and opportunities for redox metabolomics and personalized medicine. Antioxid Redox Signal 27:684–712. https://doi.org/10.1089/ars.2017.7083CrossRefPubMedPubMedCentral

95.

Maxwell PH, Ratcliffe PJ (2002) Oxygen sensors and angiogenesis. Semin Cell Dev Biol 13:29–37. https://doi.org/10.1006/scdb.2001.0287CrossRefPubMed

96.

Ke Q, Costa M (2006) Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 70:1469–1480. https://doi.org/10.1124/mol.106.027029CrossRefPubMed

97.

Distler O, Distler JHW, Scheid A et al (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95:109–116. https://doi.org/10.1161/01.RES.0000134644.89917.96CrossRefPubMed

98.

Grunewald M, Avraham I, Dor Y et al (2006) VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124:175–189. https://doi.org/10.1016/j.cell.2005.10.036CrossRefPubMed

99.

Distler JHW, Jüngel A, Pileckyte M et al (2007) Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 56:4203–4215. https://doi.org/10.1002/art.23074CrossRefPubMed

100.

Falanga V, Tiegs SL, Alstadt SP et al (1987) Transforming growth factor-beta: Selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis. J Invest Dermatol 89:100–104. https://doi.org/10.1111/1523-1747.ep12580445CrossRefPubMed

101.

Bertolotti M, Sitia R, Rubartelli A (2012) On the redox control of B lymphocyte differentiation and function. Antioxid Redox Signal 16:1139–1149. https://doi.org/10.1089/ars.2011.4252CrossRefPubMed

102.

O’Reilly S, Hugle T, van Laar JM (2012) T cells in systemic sclerosis: a reappraisal. Rheumatology 51:1540–1549. https://doi.org/10.1093/rheumatology/kes090CrossRefPubMed

103.

Mo C, Zeng Z, Deng Q et al (2018) Imbalance between T helper 17 and regulatory T cell subsets plays a significant role in the pathogenesis of systemic sclerosis. Biomed Pharmacother 108:177–183. https://doi.org/10.1016/j.biopha.2018.09.037CrossRefPubMed

104.

Abais JM, Xia M, Zhang Y et al (2015) Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector? Antioxid Redox Signal 22:1111–1129. https://doi.org/10.1089/ars.2014.5994CrossRefPubMedPubMedCentral

105.

Taroni JN, Greene CS, Martyanov V et al (2017) A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Med 9:27. https://doi.org/10.1186/s13073-017-0417-1CrossRefPubMedPubMedCentral

106.

Dantas AT, Gonçalves SMC, De AAR et al (2016) Reassessing the role of the active TGF- β 1 as a biomarker in systemic sclerosis: association of serum levels with clinical manifestations. Dis Markers 2016:1–6. https://doi.org/10.1155/2016/6064830CrossRef

107.

Meng C, Chen X, Li J et al (2008) Expression of MMP-9 and TIMP-1 in lesions of systemic sclerosis and its implications. J Huazhong Univ Sci Technol - Med Sci 28:480–482. https://doi.org/10.1007/s11596-008-0424-yCrossRef

108.

Manetti M, Guiducci S, Romano E et al (2012) Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis 71:1064–1072. https://doi.org/10.1136/annrheumdis-2011-200837CrossRefPubMed

109.

Asano Y, Ihn H, Kubo M et al (2006) Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis. Rheumatology 45:303–307. https://doi.org/10.1093/rheumatology/kei143CrossRefPubMed

110.

Casciola-Rosen L, Wigley F, Rosen A (1997) Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 185:71–79. https://doi.org/10.1084/jem.185.1.71CrossRefPubMedPubMedCentral

111.

Iwata Y, Ogawa F, Komura K et al (2007) Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress. Rheumatology 46:790–795. https://doi.org/10.1093/rheumatology/kem010CrossRefPubMed

112.

Ogawa F, Shimizu K, Hara T et al (2010) Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide reductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular damage. Arch Dermatol Res 302:27–35. https://doi.org/10.1007/s00403-009-0996-9CrossRefPubMed

113.

Dziedzic R, Wójcik K, Olchawa M et al (2023) Increased oxidative stress response in circulating blood of systemic sclerosis patients—relation to disease characteristics and inflammatory blood biomarkers. Semin Arthritis Rheum 62:152228. https://doi.org/10.1016/j.semarthrit.2023.152228CrossRefPubMed

114.

McMahan ZH, Wigley FM, Casciola-Rosen L (2017) Risk of digital vascular events in scleroderma patients who have both anticentromere and anti–interferon-inducible protein 16 antibodies. Arthritis Care Res 69:922–926. https://doi.org/10.1002/acr.22978CrossRef

115.

Gigante A, Margiotta D, Navarini L et al (2018) Serum level of endostatin and digital ulcers in systemic sclerosis patients. Int Wound J 15:424–428. https://doi.org/10.1111/iwj.12882CrossRefPubMedPubMedCentral

116.

Schiopu E, Au KM, McMahon MA et al (2014) Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound. Rheumatology 53:704–713. https://doi.org/10.1093/rheumatology/ket411CrossRefPubMed

117.

Habe K, Wada H, Higashiyama A et al (2018) The plasma levels of ADAMTS-13, von Willebrand factor, VWFpp, and fibrin-related markers in patients with systemic sclerosis having thrombosis. Clin Appl Thromb 24:920–927. https://doi.org/10.1177/1076029617736382CrossRef

118.

Kovacs G, Olschewski H (2019) Potential role of exercise echocardiography and right heart catheterization in the detection of early pulmonary vascular disease in patients with systemic sclerosis. J Scleroderma Relat Disord 4:219–224. https://doi.org/10.1177/2397198319849805CrossRefPubMedPubMedCentral

119.

Elshamy HA, Ibrahim SE, Farouk HM et al (2011) N-Terminal pro-brain natriuretic peptide in systemic sclerosis: new insights. Eur J Dermatology 21:686–690. https://doi.org/10.1684/ejd.2011.1423CrossRef

120.

Jha M, Wang M, Steele R et al (2022) NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: findings from the Canadian Scleroderma Research Group. J Scleroderma Relat Disord 7:62–70. https://doi.org/10.1177/23971983211040608CrossRefPubMed

121.

Kill A, Tabeling C, Undeutsch R et al (2014) Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 16:R29. https://doi.org/10.1186/ar4457CrossRefPubMedPubMedCentral

122.

Lammi MR, Saketkoo LA, Okpechi SC et al (2019) Microparticles in systemic sclerosis: potential pro-inflammatory mediators and pulmonary hypertension biomarkers. Respirology 24:675–683. https://doi.org/10.1111/resp.13500CrossRefPubMedPubMedCentral

123.

Panse KD, Felkin LE, López-Olañeta MM et al (2012) Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes. J Cardiovasc Transl Res 5:814–826. https://doi.org/10.1007/s12265-012-9400-9CrossRefPubMed

124.

Izumiya Y, Jinnn M, Kimura Y et al (2015) Expression of Let-7 family microRNAs in skin correlates negatively with severity of pulmonary hypertension in patients with systemic scleroderma. IJC Hear Vasc 8:98–102. https://doi.org/10.1016/j.ijcha.2015.06.006CrossRef

125.

Sun Q, Hackler J, Hilger J et al (2020) Selenium and copper as biomarkers for pulmonary arterial hypertension in systemic sclerosis. Nutrients 12:1–13. https://doi.org/10.3390/nu12061894CrossRef

126.

Perelas A, Silver RM, Arrossi AV, Highland KB (2020) Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med 8:304–320. https://doi.org/10.1016/S2213-2600(19)30480-1CrossRefPubMed

127.

Bütikofer L, Varisco PA, Distler O et al (2020) ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis. Arthritis Res Ther 22:59. https://doi.org/10.1186/s13075-020-2141-2CrossRefPubMedPubMedCentral

128.

Torrisi SE, Palmucci S, Stefano A et al (2018) Assessment of survival in patients with idiopathic pulmonary fibrosis using quantitative HRCT indexes. Multidiscip Respir Med 13:43. https://doi.org/10.1186/s40248-018-0155-2CrossRefPubMedPubMedCentral

129.

Moradzadeh M, Aghaei M, Mehrbakhsh Z et al (2021) Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis. Clin Rheumatol 40:3897–3918. https://doi.org/10.1007/s10067-021-05698-4CrossRefPubMed

130.

Mouawaid JE, Feghali-Bostwick C (2023) The molecular mechanism of systemic sclerosis-associated lung fibrosis 24:2963. https://doi.org/10.3390/ijms24032963CrossRef

131.

Decker P, Moulinet T, Lopez B et al (2021) Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases. Eur J Intern Med 91:45–52. https://doi.org/10.1016/j.ejim.2021.04.020CrossRefPubMed

132.

Lee JS, Lee EY, Ha Y-J et al (2019) Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther 21:58. https://doi.org/10.1186/s13075-019-1835-9CrossRefPubMedPubMedCentral

133.

Leong E, Bezuhly M, Marshall JS (2021) Distinct metalloproteinase expression and functions in systemic sclerosis and fibrosis: what we know and the potential for intervention. Front Physiol 12(12):72745. https://doi.org/10.3389/fphys.2021.727451CrossRef

134.

Weigold F, Günther J, Pfeiffenberger M et al (2018) Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis. Arthritis Res Ther 20:52. https://doi.org/10.1186/s13075-018-1545-8CrossRefPubMedPubMedCentral

135.

Dichev V, Mehterov NH, Kazakova MH et al (2021) Serum protein levels of YKL-40 and plasma miR-214 expression in patients with systemic sclerosis. Mod Rheumatol 31:1010–1018. https://doi.org/10.1080/14397595.2020.1859726CrossRefPubMed

136.

Suga M, Iyonaga K, Ichiyasu H et al (1999) Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur Respir J 14:376–382. https://doi.org/10.1034/j.1399-3003.1999.14b23.xCrossRefPubMed

137.

Grosicka A, Manasar A, Kucharz EJ, Kotyla PJ (2018) Serum concentration of surfactant protein D in patients with systemic sclerosis: the potential marker of the interstitial lung disease severity. Best Pract Res Clin Rheumatol 32:541–549. https://doi.org/10.1016/j.berh.2019.01.005CrossRefPubMed

138.

Wang K, Ju Q, Cao J et al (2017) Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis. Medicine (Baltimore) 96:e7083. https://doi.org/10.1097/MD.0000000000007083CrossRefPubMed

139.

Elhai M, Avouac J, Hoffmann-Vold AM et al (2016) OX40L blockade protects against inflammationdriven fibrosis. Proc Natl Acad Sci U S A 113:E3901–E3910. https://doi.org/10.1073/pnas.1523512113CrossRefPubMedPubMedCentral

140.

Żółkiewicz J, Stochmal A, Rudnicka L (2019) The role of adipokines in systemic sclerosis: a missing link? Arch Dermatol Res 311:251–263. https://doi.org/10.1007/s00403-019-01893-1CrossRefPubMedPubMedCentral

141.

Kawabata K, Makino T, Makino K et al (2020) IL-16 expression is increased in the skin and sera of patients with systemic sclerosis. Rheumatol (United Kingdom) 59:519–523. https://doi.org/10.1093/rheumatology/kez318CrossRef

142.

Leodori G, Pellicano C, Basile V et al (2022) Serum adiponectin, a novel biomarker correlates with skin thickness in systemic sclerosis. J Pers Med 12:1737. https://doi.org/10.3390/jpm12101737CrossRefPubMedPubMedCentral

143.

Farina G, Lafyatis D, Lemaire R, Farina LG, R, (2010) A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 62:580–588. https://doi.org/10.1002/art.27220CrossRefPubMedPubMedCentral

144.

Stern EP, Guerra SG, Chinque H et al (2020) Analysis of anti-RNA polymerase III antibody-positive systemic sclerosis and altered GPATCH2L and CTNND2 expression in scleroderma renal crisis. J Rheumatol 47:1668–1677. https://doi.org/10.3899/jrheum.190945CrossRefPubMed

145.

Okrój M, Johansson M, Saxne T et al (2016) Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis. Arthritis Res Ther 18:267. https://doi.org/10.1186/s13075-016-1168-xCrossRefPubMedPubMedCentral

146.

Nguyen AD, Andréasson K, McMahan ZH et al (2023) Gastrointestinal tract involvement in systemic sclerosis: the roles of diet and the microbiome. Semin Arthritis Rheum 60:152185. https://doi.org/10.1016/j.semarthrit.2023.152185CrossRefPubMedPubMedCentral

147.

Andréasson K, Scheja A, Saxne T et al (2011) Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis. J Intern Med 270:50–57. https://doi.org/10.1111/j.1365-2796.2010.02340.xCrossRefPubMed

148.

Goldblatt F, Gordon TP, Waterman SA (2002) Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology 123:1144–1150. https://doi.org/10.1053/gast.2002.36057CrossRefPubMed

149.

Hamberg V, Wallman JK, Mogard E et al (2023) Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis. Rheumatol Int 43:961–967. https://doi.org/10.1007/s00296-022-05264-4CrossRefPubMed

150.

Weeding E, Casciola-Rosen L, Shah AA (2020) Cancer and scleroderma. Rheum Dis Clin North Am 46:551–564. https://doi.org/10.1016/j.rdc.2020.03.002CrossRefPubMedPubMedCentral

151.

Guillen-Del-Castillo A, Simeón-Aznar CP (2023) Identifying the risk of cancer-associated systemic sclerosis. Joint Bone Spine 90:105618. https://doi.org/10.1016/j.jbspin.2023.105618CrossRefPubMed

152.

Onishi A, Sugiyama D, Kumagai S, Morinobu A (2013) Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 65:1913–1921. https://doi.org/10.1002/art.37969CrossRefPubMed

153.

Sargin G, Senturk T, Cildag S (2018) Systemic sclerosis and malignancy. Int J Rheum Dis 21:1093–1097. https://doi.org/10.1111/1756-185X.13311CrossRefPubMed

154.

Hoa S, Lazizi S, Baron M et al (2022) Association between autoantibodies in systemic sclerosis and cancer in a national registry. Rheumatology (Oxford) 61:2905–2914. https://doi.org/10.1093/rheumatology/keab735CrossRefPubMed

155.

Di Battista M, Lepri G, Codullo V et al (2023) Systemic sclerosis: one year in review. Clin Exp Rheumatol 41:1567–1574. https://doi.org/10.55563/clinexperheumatol/ki76s5CrossRefPubMed

156.

Hummers LK (2023) Clinical trials in systemic sclerosis: crossroads and opportunities. Arthritis Rehumatol 75:1328–1330. https://doi.org/10.1002/art.42524CrossRef

157.

Campochiaro C, Allanore Y (2021) An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years. Arthritis Res Ther 23:155. https://doi.org/10.1186/s13075-021-02536-5CrossRefPubMedPubMedCentral

158.

Khanna D, Kramer F, Höfler J et al (2024) Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 9:keae150. https://doi.org/10.1093/rheumatology/keae150CrossRef

Title: Biomarkers reflecting the pathogenesis, clinical manifestations, and guide therapeutic approach in systemic sclerosis: a narrative review
Authors: Anna Bazsó
Péter Szodoray Med Dsci
Yehuda Shoenfeld
Emese Kiss Med Dsci
Publication date: 29-08-2024
Publisher: Springer International Publishing
Keywords: Systemic Sclerosis
Biomarkers
Pulmonary Hypertension
Pulmonary Hypertension
Pulmonary Hypertension
Pulmonary Hypertension
Published in: Clinical Rheumatology
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-024-07123-y

2024 ESC Congress

Noise pollution dangerous for heart health

02-09-2024
Myocardial Infarction
News

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Antihypertensives: more effective at morning or night?

02-09-2024
Hypertension
News

Low Lp(a) levels unlikely to increase the risk of diabetes

02-09-2024
Type 2 Diabetes
News

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

EASD 2024

Springer Medicine

Biomarkers reflecting the pathogenesis, clinical manifestations, and guide therapeutic approach in systemic sclerosis: a narrative review

Abstract

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials

EASD 2024

Springer Medicine

Abstract

Please log in to get access to this content

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials